Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Tsuyoshi Hamada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3937-2755; OpenAlex author ID A5067201661, A5113266894. Sources: OpenAlex.

Their work

Papers
46 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
118
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 4 papers · 2014: 6 papers · 2015: 3 papers · 2016: 1 paper · 2017: 2 papers · 2018: 4 papers · 2019: 3 papers · 2020: 3 papers · 2021: 2 papers · 2022: 1 paper · 2023: 6 papers · 2024: 1 paper · 2025: 7 papers · 2026: 2 papers

Papers 46

  1. Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. Co-author DOI 10.1038/s41416-025-03308-7↗
  2. Intraductal Papillary Mucinous Neoplasm and Pancreatic Cancer: Opportunity Knocks Twice. Co-author DOI 10.14309/ajg.0000000000003677↗
  3. Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT d… Co-author DOI 10.1007/s00535-024-02173-0↗
  4. Factors associated with actionable gene aberrations in pancreatic cancer based on the C-CAT database. Co-author DOI 10.1007/s00535-025-02253-9↗
  5. Relationship of Intrapancreatic Fat Deposition With Pancreatic Cancer Differs According to Carcinoma Types. First author DOI 10.1053/j.gastro.2025.04.032↗
  6. Risk factors for pancreatic cancer in individuals with intraductal papillary mucinous neoplasms and no high-risk stigmata during up to 5 years of surveillance:… Co-author DOI 10.1136/gutjnl-2024-333259↗
  7. Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens. Co-author DOI 10.1245/s10434-025-17289-7↗
  8. ASO Author Reflections: Blood Group as a Guide for Adjuvant Chemotherapy in Pancreatic Cancer. Last author DOI 10.1245/s10434-025-17381-y↗
  9. Endoscopic ultrasound-guided hepaticogastrostomy and endoscopic retrograde cholangiopancreatography-guided biliary drainage for distal malignant biliary obstru… Co-author DOI 10.5946/ce.2024.031↗
  10. Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.10.001↗
  11. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. Co-author DOI 10.1002/cjp2.323↗
  12. Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospec… Co-author DOI 10.1007/s00520-023-07659-w↗
  13. Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-022-01939-8↗
  14. A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal… Co-author DOI 10.1007/s00535-023-02020-8↗
  15. Gemcitabine plus nab-paclitaxel for pancreatic cancer and interstitial lung disease: A nationwide longitudinal study. Co-author DOI 10.1111/cas.15910↗
  16. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic C… Co-author DOI 10.3390/cancers15020358↗
  17. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Co-author DOI 10.1111/cas.15398↗
  18. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis. Co-author DOI 10.1007/s10637-020-00982-7↗
  19. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. Co-author DOI 10.1007/s10637-020-01022-0↗
  20. Response to the letter by Lai et al. regarding our manuscript "Statin use and pancreatic cancer risk in two prospective cohort studies". Co-author DOI 10.1007/s00535-020-01676-w↗
  21. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-19-1315↗
  22. Screening Strategy of Pancreatic Cancer in Patients with Diabetes Mellitus. Co-author DOI 10.3390/diagnostics10080572↗
  23. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s10637-018-0691-9↗
  24. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Co-author DOI 10.1038/s41416-019-0426-5↗
  25. Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival. Co-author DOI 10.1158/1055-9965.epi-19-0577↗
  26. Statin use and pancreatic cancer risk in two prospective cohort studies. Co-author DOI 10.1007/s00535-018-1430-x↗
  27. Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2018.02.022↗
  28. Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studie… Co-author DOI 10.1053/j.gastro.2017.12.001↗
  29. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001079↗
  30. The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1097/mpa.0000000000000767↗
  31. Thromboembolisms in Advanced Pancreatic Cancer: A Retrospective Analysis of 475 Patients. Co-author DOI 10.1097/mpa.0000000000000889↗
  32. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2016.05.016↗
  33. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Co-author DOI 10.1007/s00432-014-1873-2↗
  34. Pancreatic cancer with malignant ascites: clinical features and outcomes. Co-author DOI 10.1097/mpa.0000000000000290↗
  35. [IPMN and pancreatic cyst as high risk of pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.1474↗
  36. A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. Co-author DOI 10.1007/s00280-014-2563-0↗
  37. Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. Co-author DOI 10.1007/s12029-014-9603-1↗
  38. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Co-author DOI 10.1038/bjc.2014.131↗
  39. A R0 resection case of initially unresectable metastatic pancreatic cancer downstaged by FOLFIRINOX therapy. Co-author DOI 10.1097/mpa.0000000000000139↗
  40. Smoking, family history of cancer, and diabetes mellitus are associated with the age of onset of pancreatic cancer in Japanese patients. Co-author DOI 10.1097/mpa.0000000000000158↗
  41. Risk factors for covered metallic stent migration in patients with distal malignant biliary obstruction due to pancreatic cancer. Co-author DOI 10.1111/jgh.12602↗
  42. Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monoth… Co-author DOI 10.1007/s00280-012-1981-0↗
  43. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Co-author DOI 10.1007/s00280-013-2278-7↗
  44. A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer. Co-author DOI 10.1007/s00280-013-2313-8↗
  45. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Co-author DOI 10.1007/s10637-013-9972-5↗
  46. Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer. Co-author DOI 10.1016/j.gie.2011.04.046↗

Closest collaborators

The 25 strongest of 118 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yousuke Nakai · 34 shared papers, 2011–2026 · strength 3.48
  2. Naminatsu Takahara · 25 shared papers, 2011–2025 · strength 2.14
  3. Mitsuhiro Fujishiro · 11 shared papers, 2022–2026 · strength 2.00
  4. Tatsunori Suzuki · 10 shared papers, 2022–2026 · strength 1.77
  5. Kazunaga Ishigaki · 14 shared papers, 2015–2025 · strength 1.76
  6. Hiroki Oyama · 7 shared papers, 2020–2026 · strength 1.46
  7. Yohei Masugi · 7 shared papers, 2020–2026 · strength 1.27
  8. Kazuhiko Koike · 23 shared papers, 2011–2022 · strength 1.17
  9. Manabu Takamatsu · 6 shared papers, 2022–2026 · strength 1.15
  10. Naoki Sasahira · 13 shared papers, 2011–2026 · strength 1.15
  11. Tsuyoshi Takeda · 9 shared papers, 2015–2026 · strength 1.11
  12. Kei Saito · 13 shared papers, 2014–2023 · strength 1.04
  13. Hirofumi Kogure · 21 shared papers, 2011–2021 · strength 1.02
  14. Suguru Mizuno · 20 shared papers, 2011–2021 · strength 0.99
  15. Hiroyuki Isayama · 21 shared papers, 2011–2021 · strength 0.95
  16. Maxim S. Petrov · 3 shared papers, 2025–2026 · strength 0.83
  17. Kiyoshi Hasegawa · 5 shared papers, 2022–2026 · strength 0.83
  18. Yu Takahashi · 5 shared papers, 2022–2026 · strength 0.79
  19. Tomotaka Saito · 9 shared papers, 2014–2023 · strength 0.72
  20. Minoru Tada · 18 shared papers, 2011–2019 · strength 0.71
  21. Koji Miyabayashi · 12 shared papers, 2013–2025 · strength 0.71
  22. Yosuke Inoue · 4 shared papers, 2022–2026 · strength 0.63
  23. Minoru Kitago · 4 shared papers, 2022–2026 · strength 0.63
  24. Sho Uemura · 4 shared papers, 2022–2026 · strength 0.63
  25. Brian Matthew Wolpin · 7 shared papers, 2018–2020 · strength 0.62

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.